The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Certolizumab Pegol Usage Compatible with Breastfeeding

Certolizumab Pegol Usage Compatible with Breastfeeding

December 20, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270In 2012, a review reported on the safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease.1 Many of these agents—particularly tumor necrosis factor inhibitors (TNFi), such as adalimumab, certolizumab pegol and infliximab—are also used to treat rheumatoid arthritis (RA). In their review, the authors note that use of adalimumab and infliximab are compatible with breastfeeding, with very low drug amounts that would not harm an infant reported in breast milk. In the case of infliximab, any amount transferred to breast milk would, most likely, be inactivated by digestive enzymes in the neonate. However, these data are mostly not validated.

You Might Also Like
  • Transfer of Certolizumab in Breast Milk Not a Concern
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
Also By This Author
  • Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab

Certolizumab pegol has been considered compatible with breastfeeding, although no human data have existed until now. Data from a multicenter, postmarketing study evaluated the concentration of certolizumab pegol (Cimzia) in Mature Breast Milk of Lactating Mothers (CRADLE).2 This is the first study designed to determine certolizumab pegol concentrations in human breast milk and estimate the average daily amount of certolizumab pegol potentially ingested by infants.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lactating mothers (n=17) being treated for RA (n=7), Crohn’s disease (n=5), psoriatic arthritis (n=3) or axial spondyloarthritis/ankylosing spondylitis (n=2) who had received at least three doses of certolizumab pegol and were at least six weeks postpartum were enrolled in the study. Breast milk samples were collected following steady state (≥3 doses) on Days 0, 2, 4, 6, 8, 10, 12 and 14 (±28) from each lactating mother across one dosing period. The sampling period occurred at Day 14 for the dose of 200 mg certolizumab pegol every two weeks, and on Day 28 for 400 mg certolizumab pegol every four weeks. Certolizumab pegol levels in breast milk were analyzed with a highly sensitive certolizumab pegol-specific ELISA assay.

Eighteen mothers entered the study, but only 17 mothers were sampled. Of these, 16 received 200 mg certolizumab pegol every two weeks, and one received 400 mg certolizumab pegol every four weeks. The average age of the mothers was 33.7 years. The average gestational age of the infants was 39.9 weeks, with an average birth weight of 3.4 kg. Eleven infants (64.7%) were female.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Validated in milk, the lower limit of quantification was 0.032 μg/mL, which was 10-fold lower than assays used in certolizumab pegol pharmacokinetic studies. Four of 17 mothers’ samples had no measurable certolizumab pegol levels in their breast milk, while 13 of 17 had quantifiable levels at any time point. The highest concentration of certolizumab pegol in breast milk was 0.076 μg/mL. The estimated average daily infant dose ranged from 0 mg/kg per day to 0.0104 mg/kg per day.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: breast milk, breastfeeding, Certolizumab Pegol, infants, pregnancy

You Might Also Like:
  • Transfer of Certolizumab in Breast Milk Not a Concern
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients
  • Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)